{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:29:53Z","timestamp":1793312993926,"version":"4.5.0"},"reference-count":104,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":413,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RF1MH126723"],"award-info":[{"award-number":["RF1MH126723"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012312","name":"Robert Packard Center for ALS Research, Johns Hopkins University","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100012312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013013","name":"Target ALS","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100013013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000923","name":"Silicon Valley Community Foundation","doi-asserted-by":"publisher","award":["221722"],"award-info":[{"award-number":["221722"]}],"id":[{"id":"10.13039\/100000923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH1910117"],"award-info":[{"award-number":["W81XWH1910117"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH2010241"],"award-info":[{"award-number":["W81XWH2010241"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000971","name":"Amyotrophic Lateral Sclerosis Association","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100000971","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014761","name":"Hope Center for Neurological Disorders","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100014761","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s13311-022-01247-2","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T10:02:46Z","timestamp":1654164166000},"page":"1145-1158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":100,"title":["Antisense Oligonucleotides for the Study and Treatment of ALS"],"prefix":"10.1016","volume":"19","author":[{"given":"Benjamin D.","family":"Boros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Schoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collin J.","family":"Kreple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3424-5511","authenticated-orcid":false,"given":"Timothy M.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10107","key":"10.1007\/s13311-022-01247-2_bib1","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(17)31287-4","article-title":"Amyotrophic lateral sclerosis","volume":"390","author":"van Es","year":"2017","journal-title":"Lancet"},{"issue":"6415","key":"10.1007\/s13311-022-01247-2_bib2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/362059a0","article-title":"Mutations in Cu\/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis","volume":"362","author":"Rosen","year":"1993","journal-title":"Nature"},{"issue":"1","key":"10.1007\/s13311-022-01247-2_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nn.3584","article-title":"State of play in amyotrophic lateral sclerosis genetics","volume":"17","author":"Renton","year":"2014","journal-title":"Nat Neurosci"},{"issue":"3","key":"10.1007\/s13311-022-01247-2_bib4","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S1474-4422(12)70014-5","article-title":"Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study","volume":"11","author":"Byrne","year":"2012","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1007\/s13311-022-01247-2_bib5","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuron.2011.09.010","article-title":"A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD","volume":"72","author":"Renton","year":"2011","journal-title":"Neuron"},{"issue":"2","key":"10.1007\/s13311-022-01247-2_bib6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","article-title":"Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS","volume":"72","author":"DeJesus-Hernandez","year":"2011","journal-title":"Neuron"},{"issue":"7628","key":"10.1007\/s13311-022-01247-2_bib7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nature20413","article-title":"Decoding ALS: from genes to mechanism","volume":"539","author":"Taylor","year":"2016","journal-title":"Nature"},{"issue":"6","key":"10.1007\/s13311-022-01247-2_bib8","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.neuron.2017.04.010","article-title":"Antisense oligonucleotides: translation from mouse models to human neurodegenerative diseases","volume":"94","author":"Schoch","year":"2017","journal-title":"Neuron"},{"key":"10.1007\/s13311-022-01247-2_bib9","doi-asserted-by":"crossref","unstructured":"Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020;1\u201322.","DOI":"10.1038\/s41573-020-0075-7"},{"issue":"1","key":"10.1007\/s13311-022-01247-2_bib10","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu Rev Pharmacol"},{"issue":"2","key":"10.1007\/s13311-022-01247-2_bib11","first-page":"e323","article-title":"Antisense oligonucleotides. Neurology","volume":"5","author":"Scoles","year":"2019","journal-title":"Genetics"},{"issue":"12","key":"10.1007\/s13311-022-01247-2_bib12","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/nbt1042","article-title":"Antisense and siRNA as agonists of Toll-like receptors","volume":"22","author":"Agrawal","year":"2004","journal-title":"Nat Biotechnol"},{"issue":"6","key":"10.1007\/s13311-022-01247-2_bib13","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41587-019-0106-2","article-title":"Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index","volume":"37","author":"Shen","year":"2019","journal-title":"Nat Biotechnol"},{"issue":"9","key":"10.1007\/s13311-022-01247-2_bib14","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/sj.mt.6300240","article-title":"2\u2032-O-methyl-modified RNAs act as TLR7 antagonists","volume":"15","author":"Robbins","year":"2007","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-022-01247-2_bib15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv Drug Deliver Rev"},{"issue":"9","key":"10.1007\/s13311-022-01247-2_bib16","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nbt.3948","article-title":"Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides","volume":"35","author":"Iwamoto","year":"2017","journal-title":"Nat Biotechnol"},{"issue":"18","key":"10.1007\/s13311-022-01247-2_bib17","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","article-title":"Treatment of HCV Infection by Targeting MicroRNA","volume":"368","author":"Janssen","year":"2013","journal-title":"New Engl J Medicine"},{"issue":"2","key":"10.1007\/s13311-022-01247-2_bib18","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.24555","article-title":"Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy","volume":"79","author":"Mendell","year":"2016","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1007\/s13311-022-01247-2_bib19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.drudis.2017.09.018","article-title":"Locked nucleic acid: modality, diversity, and drug discovery","volume":"23","author":"Hagedorn","year":"2018","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1007\/s13311-022-01247-2_bib20","doi-asserted-by":"crossref","first-page":"30377","DOI":"10.1038\/srep30377","article-title":"Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides","volume":"6","author":"Kasuya","year":"2016","journal-title":"Sci Rep-uk."},{"key":"10.1007\/s13311-022-01247-2_bib21","article-title":"Quantifying and mitigating motor phenotypes induced by antisense oligonucleotides in the central nervous system","author":"Moazami","year":"2021","journal-title":"Biorxiv."},{"issue":"17","key":"10.1007\/s13311-022-01247-2_bib22","doi-asserted-by":"crossref","first-page":"17181","DOI":"10.1074\/jbc.M311683200","article-title":"Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs*","volume":"279","author":"Wu","year":"2004","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1007\/s13311-022-01247-2_bib23","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/j.1742-4658.2009.06908.x","article-title":"Ribonuclease H: the enzymes in eukaryotes","volume":"276","author":"Cerritelli","year":"2009","journal-title":"Febs J"},{"issue":"14","key":"10.1007\/s13311-022-01247-2_bib24","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1093\/nar\/gkw533","article-title":"Splice-switching antisense oligonucleotides as therapeutic drugs","volume":"44","author":"Havens","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"10.1007\/s13311-022-01247-2_bib25","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/s41594-020-0465-x","article-title":"Decoding mRNA translatability and stability from the 5\u2032 UTR","volume":"27","author":"Jia","year":"2020","journal-title":"Nat Struct Mol Biol"},{"issue":"6","key":"10.1007\/s13311-022-01247-2_bib26","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41583-018-0011-6","article-title":"The power of 3\u2032 UTRs","volume":"19","author":"Bray","year":"2018","journal-title":"Nat Rev Neurosci"},{"issue":"8","key":"10.1007\/s13311-022-01247-2_bib27","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nrg1125","article-title":"The power of the 3\u2032 UTR: translational control and development","volume":"4","author":"Kuersten","year":"2003","journal-title":"Nat Rev Genet"},{"issue":"2","key":"10.1007\/s13311-022-01247-2_bib28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/15476910600718236","article-title":"CpG and non-CpG oligodeoxynucleotides induce differential proinflammatory gene expression profiles in liver and peripheral blood leukocytes in mice","volume":"3","author":"Younis","year":"2008","journal-title":"J Immunotoxicol"},{"issue":"2","key":"10.1007\/s13311-022-01247-2_bib29","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2003715","article-title":"Phase 1\u20132 trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"383","author":"Miller","year":"2020","journal-title":"New Engl J Med"},{"issue":"5","key":"10.1007\/s13311-022-01247-2_bib30","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","article-title":"An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study","volume":"12","author":"Miller","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-022-01247-2_bib31","unstructured":"Miller T, Cudkowicz M. Results from the phase 3 VALOR study and its open-label extension: evaluating the clinical efficacy and safety of tofersen in adults with ALS and confirmed SOD1 mutation. American Neurological Association; 2021."},{"issue":"3","key":"10.1007\/s13311-022-01247-2_bib32","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1089\/nat.2018.0721","article-title":"Lipid nanoparticles enabling gene therapies: from concepts to clinical utility","volume":"28","author":"Kulkarni","year":"2018","journal-title":"Nucleic Acid Ther"},{"issue":"1","key":"10.1007\/s13311-022-01247-2_bib33","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13023-015-0326-6","article-title":"Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study","volume":"10","author":"Suhr","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1007\/s13311-022-01247-2_bib34","doi-asserted-by":"crossref","unstructured":"Nagata T, Dwyer CA, Yoshida-Tanaka K, Ihara K, Ohyagi M, Kaburagi H, et al. Cholesterol-functionalized DNA\/RNA heteroduplexes cross the blood\u2013brain barrier and knock down genes in the rodent CNS. Nat Biotechnol. 2021;1\u20138.","DOI":"10.1038\/s41587-021-00972-x"},{"issue":"18","key":"10.1007\/s13311-022-01247-2_bib35","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"New Engl J Medicine"},{"key":"10.1007\/s13311-022-01247-2_bib36","unstructured":"U.S. Food and Drug Administration. FDA approves first drug for spinal muscular atrophy [Internet]. 2016. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-spinal-muscular-atrophy. Accessed 27 Apr 2022."},{"issue":"7","key":"10.1007\/s13311-022-01247-2_bib37","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/jnnp-2016-315018","article-title":"Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis","volume":"88","author":"Zou","year":"2017","journal-title":"J Neurology Neurosurg Psychiatry"},{"issue":"5166","key":"10.1007\/s13311-022-01247-2_bib38","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1126\/science.8209258","article-title":"Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation","volume":"264","author":"Gurney","year":"1994","journal-title":"Science"},{"issue":"1","key":"10.1007\/s13311-022-01247-2_bib39","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/ng0596-43","article-title":"Motor neurons in Cu\/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury","volume":"13","author":"Reaume","year":"1996","journal-title":"Nat Genet"},{"issue":"10","key":"10.1007\/s13311-022-01247-2_bib40","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41593-018-0236-8","article-title":"Animal models of neurodegenerative diseases","volume":"21","author":"Dawson","year":"2018","journal-title":"Nat Neurosci"},{"issue":"1","key":"10.1007\/s13311-022-01247-2_bib41","first-page":"5","article-title":"Rodent models of amyotrophic lateral sclerosis","volume":"69","author":"Philips","year":"2015","journal-title":"Curr Protoc Pharmacol"},{"issue":"2","key":"10.1007\/s13311-022-01247-2_bib42","first-page":"659","article-title":"SOD1 mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model","volume":"118","author":"Harraz","year":"2008","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1007\/s13311-022-01247-2_bib43","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.neuron.2004.06.016","article-title":"Toxicity of familial ALS-linked SOD1 mutants from selective recruitment to spinal mitochondria","volume":"43","author":"Liu","year":"2004","journal-title":"Neuron"},{"issue":"3","key":"10.1007\/s13311-022-01247-2_bib44","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1073\/pnas.032539299","article-title":"Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS)","volume":"99","author":"Howland","year":"2002","journal-title":"Proc National Acad Sci"},{"issue":"8","key":"10.1007\/s13311-022-01247-2_bib45","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1172\/JCI25424","article-title":"Antisense oligonucleotide therapy for neurodegenerative disease","volume":"116","author":"Smith","year":"2006","journal-title":"J Clin Investig"},{"issue":"8","key":"10.1007\/s13311-022-01247-2_bib46","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1172\/JCI99081","article-title":"Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models","volume":"128","author":"McCampbell","year":"2018","journal-title":"J Clin Investig"},{"issue":"7","key":"10.1007\/s13311-022-01247-2_bib47","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1172\/JCI80705","article-title":"In vivo kinetic approach reveals slow SOD1 turnover in the CNS","volume":"125","author":"Crisp","year":"2015","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1007\/s13311-022-01247-2_bib48","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/acn3.657","article-title":"Protein production is an early biomarker for RNA-targeted therapies","volume":"5","author":"Self","year":"2018","journal-title":"Ann Clin Transl Neur"},{"issue":"1","key":"10.1007\/s13311-022-01247-2_bib49","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40478-016-0340-5","article-title":"From animal models to human disease: a genetic approach for personalized medicine in ALS","volume":"4","author":"Picher-Martel","year":"2016","journal-title":"Acta Neuropathologica Commun"},{"issue":"2","key":"10.1007\/s13311-022-01247-2_bib50","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1136\/jnnp-2016-313521","article-title":"Defining SOD1 ALS natural history to guide therapeutic clinical trial design","volume":"88","author":"Bali","year":"2017","journal-title":"J Neurology Neurosurg Psychiatry"},{"issue":"1","key":"10.1007\/s13311-022-01247-2_bib51","doi-asserted-by":"crossref","first-page":"17071","DOI":"10.1038\/nrdp.2017.71","article-title":"Amyotrophic lateral sclerosis","volume":"3","author":"Hardiman","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10.1007\/s13311-022-01247-2_bib52","first-page":"a024224","article-title":"Disease mechanisms of C9ORF72 repeat expansions","volume":"8","author":"Gendron","year":"2018","journal-title":"Csh Perspect Med"},{"issue":"14","key":"10.1007\/s13311-022-01247-2_bib53","doi-asserted-by":"crossref","first-page":"9860","DOI":"10.1074\/jbc.C113.452532","article-title":"The disease-associated r(GGGGCC)n repeat from the C9orf72 gene forms tract length-dependent uni- and multimolecular RNA G-quadruplex structures*","volume":"288","author":"Reddy","year":"2013","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1007\/s13311-022-01247-2_bib54","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.celrep.2013.10.049","article-title":"Hexanucleotide repeats in ALS\/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic","volume":"5","author":"Lee","year":"2013","journal-title":"Cell Rep"},{"issue":"9","key":"10.1007\/s13311-022-01247-2_bib55","first-page":"1787","article-title":"Nuclear accumulation of mRNAs underlies G4C2-repeat-induced translational repression in a cellular model of C9orf72 ALS","volume":"128","author":"Rossi","year":"2015","journal-title":"J Cell Sci"},{"issue":"4","key":"10.1007\/s13311-022-01247-2_bib56","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00401-014-1329-4","article-title":"C9orf72 FTLD\/ALS-associated Gly-Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration","volume":"128","author":"May","year":"2014","journal-title":"Acta Neuropathol"},{"issue":"4","key":"10.1007\/s13311-022-01247-2_bib57","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00401-014-1336-5","article-title":"Aggregation-prone c9FTD\/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress","volume":"128","author":"Zhang","year":"2014","journal-title":"Acta Neuropathol"},{"issue":"8","key":"10.1007\/s13311-022-01247-2_bib58","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41591-018-0071-1","article-title":"Poly(GR) impairs protein translation and stress granule dynamics in C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis","volume":"24","author":"Zhang","year":"2018","journal-title":"Nat Med"},{"key":"10.1007\/s13311-022-01247-2_bib59","doi-asserted-by":"crossref","first-page":"637548","DOI":"10.3389\/fncel.2021.637548","article-title":"Emerging perspectives on dipeptide repeat proteins in C9ORF72 ALS\/FTD","volume":"15","author":"Schmitz","year":"2021","journal-title":"Front Cell Neurosci"},{"issue":"6125","key":"10.1007\/s13311-022-01247-2_bib60","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1126\/science.1232927","article-title":"The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD\/ALS","volume":"339","author":"Mori","year":"2013","journal-title":"Science"},{"issue":"6","key":"10.1007\/s13311-022-01247-2_bib61","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00401-013-1189-3","article-title":"Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins","volume":"126","author":"Mori","year":"2013","journal-title":"Acta Neuropathol"},{"issue":"6","key":"10.1007\/s13311-022-01247-2_bib62","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00401-013-1192-8","article-title":"Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD\/ALS","volume":"126","author":"Gendron","year":"2013","journal-title":"Acta Neuropathol"},{"issue":"6279","key":"10.1007\/s13311-022-01247-2_bib63","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1126\/science.aaf1064","article-title":"C9orf72 is required for proper macrophage and microglial function in mice","volume":"351","author":"O'Rourke","year":"2016","journal-title":"Science"},{"issue":"347","key":"10.1007\/s13311-022-01247-2_bib64","doi-asserted-by":"crossref","first-page":"347ra93","DOI":"10.1126\/scitranslmed.aaf6038","article-title":"Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease","volume":"8","author":"Burberry","year":"2016","journal-title":"Sci Transl Med."},{"issue":"3","key":"10.1007\/s13311-022-01247-2_bib65","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nm.4490","article-title":"Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS\/FTD human induced motor neurons","volume":"24","author":"Shi","year":"2018","journal-title":"Nat Med"},{"issue":"5","key":"10.1007\/s13311-022-01247-2_bib66","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41593-020-0619-5","article-title":"Reduced C9ORF72 function exacerbates gain of toxicity from ALS\/FTD-causing repeat expansion in C9orf72","volume":"23","author":"Zhu","year":"2020","journal-title":"Nat Neurosci"},{"key":"10.1007\/s13311-022-01247-2_bib67","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3389\/fnins.2017.00671","article-title":"Current advances and limitations in modeling ALS\/FTD in a dish using induced pluripotent stem cells","volume":"11","author":"Guo","year":"2017","journal-title":"Front Neurosci-switz"},{"issue":"47","key":"10.1007\/s13311-022-01247-2_bib68","doi-asserted-by":"crossref","first-page":"E4530","DOI":"10.1073\/pnas.1318835110","article-title":"Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration","volume":"110","author":"Lagier-Tourenne","year":"2013","journal-title":"Proc National Acad Sci"},{"issue":"208","key":"10.1007\/s13311-022-01247-2_bib69","doi-asserted-by":"crossref","first-page":"208ra149","DOI":"10.1126\/scitranslmed.3007529","article-title":"Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion","volume":"5","author":"Sareen","year":"2013","journal-title":"Sci Transl Med."},{"issue":"2","key":"10.1007\/s13311-022-01247-2_bib70","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.neuron.2013.10.015","article-title":"RNA Toxicity from the ALS\/FTD C9ORF72 expansion is mitigated by antisense intervention","volume":"80","author":"Donnelly","year":"2013","journal-title":"Neuron"},{"key":"10.1007\/s13311-022-01247-2_bib71","doi-asserted-by":"crossref","unstructured":"Liu Y, Andreucci A, Iwamoto N, Yin Y, Yang H, Liu F, Patil S, Mohapatra S, Purcell-Estabrook E, Taborn K, Dale E, Vargeese C. WVE-004, an investigational stereopure antisense oligonucleotide for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) (2302). Neurology Apr 2021, 96 (15 Supplement) 2302.","DOI":"10.1212\/WNL.96.15_supplement.2302"},{"issue":"1","key":"10.1007\/s13311-022-01247-2_bib72","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/s41467-021-21112-8","article-title":"Variant-selective stereopure oligonucleotides protect against pathologies associated with C9orf72-repeat expansion in preclinical models","volume":"12","author":"Liu","year":"2021","journal-title":"Nat Commun"},{"key":"10.1007\/s13311-022-01247-2_bib73","doi-asserted-by":"crossref","unstructured":"Tran H, Moazami MP, Yang H, McKenna-Yasek D, Douthwright CL, Pinto C, et al. Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide. Nat Med. 2021;1\u20138.","DOI":"10.1038\/s41591-021-01557-6"},{"issue":"3","key":"10.1007\/s13311-022-01247-2_bib74","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.neuron.2016.04.006","article-title":"Gain of Toxicity from ALS\/FTD-linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs","volume":"90","author":"Jiang","year":"2016","journal-title":"Neuron"},{"issue":"5","key":"10.1007\/s13311-022-01247-2_bib75","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.neuron.2015.11.018","article-title":"Human C9ORF72 hexanucleotide expansion reproduces RNA foci and dipeptide repeat proteins but not neurodegeneration in BAC transgenic mice","volume":"88","author":"Peters","year":"2015","journal-title":"Neuron"},{"issue":"383","key":"10.1007\/s13311-022-01247-2_bib76","doi-asserted-by":"crossref","first-page":"7866","DOI":"10.1126\/scitranslmed.aai7866","article-title":"Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis","volume":"9","author":"Gendron","year":"2017","journal-title":"Sci Transl Med."},{"issue":"5","key":"10.1007\/s13311-022-01247-2_bib77","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.neuron.2014.07.041","article-title":"Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD\/ALS","volume":"83","author":"Su","year":"2014","journal-title":"Neuron"},{"issue":"17","key":"10.1007\/s13311-022-01247-2_bib78","doi-asserted-by":"crossref","first-page":"e1605","DOI":"10.1212\/WNL.0000000000008359","article-title":"Prospective natural history study of C9orf72 ALS clinical characteristics and biomarkers","volume":"93","author":"Cammack","year":"2019","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01247-2_bib79","unstructured":"Biogen and Ionis announce topline phase 1 study results of investigational drug in C9orf72 amyotrophic lateral sclerosis | Biogen [Internet]. 2022. Available from: https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-and-ionis-announce-topline-phase-1-study-results. Accessed 27 Apr 2022."},{"issue":"S1","key":"10.1007\/s13311-022-01247-2_bib80","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/jnc.13625","article-title":"Physiological functions and pathobiology of TDP-43 and FUS\/TLS proteins","volume":"138","author":"Ratti","year":"2016","journal-title":"J Neurochem"},{"issue":"13","key":"10.1007\/s13311-022-01247-2_bib81","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1093\/hmg\/ddt117","article-title":"ALS mutant FUS disrupts nuclear localization and sequesters wild-type FUS within cytoplasmic stress granules","volume":"22","author":"Vance","year":"2013","journal-title":"Hum Mol Genet"},{"issue":"5918","key":"10.1007\/s13311-022-01247-2_bib82","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.1165942","article-title":"Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6","volume":"323","author":"Vance","year":"2009","journal-title":"Science"},{"issue":"1","key":"10.1007\/s13311-022-01247-2_bib83","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40478-015-0202-6","article-title":"FUS\/TLS deficiency causes behavioral and pathological abnormalities distinct from amyotrophic lateral sclerosis","volume":"3","author":"Kino","year":"2015","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"10.1007\/s13311-022-01247-2_bib84","doi-asserted-by":"crossref","first-page":"10465","DOI":"10.1038\/ncomms10465","article-title":"ALS-associated mutant FUS induces selective motor neuron degeneration through toxic gain of function","volume":"7","author":"Sharma","year":"2016","journal-title":"Nat Commun"},{"key":"10.1007\/s13311-022-01247-2_bib85","doi-asserted-by":"crossref","unstructured":"Korobeynikov VA, Lyashchenko AK, Blanco-Redondo B, Jafar-Nejad P, Shneider NA. Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nat Med. 2022;1\u201313.","DOI":"10.1038\/s41591-021-01615-z"},{"issue":"6","key":"10.1007\/s13311-022-01247-2_bib86","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3390\/genes8060157","article-title":"Ataxin-2: from RNA control to human health and disease","volume":"8","author":"Ostrowski","year":"2017","journal-title":"Genes-basel"},{"issue":"3","key":"10.1007\/s13311-022-01247-2_bib87","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/WNO0b013e3181b416de","article-title":"The spinocerebellar ataxias","volume":"29","author":"Paulson","year":"2009","journal-title":"J Neuro-ophthalmol"},{"issue":"7310","key":"10.1007\/s13311-022-01247-2_bib88","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature09320","article-title":"Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS","volume":"466","author":"Elden","year":"2010","journal-title":"Nature"},{"issue":"1","key":"10.1007\/s13311-022-01247-2_bib89","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s40478-020-01055-9","article-title":"Intracellular dynamics of ataxin-2 in the human brains with normal and frontotemporal lobar degeneration with TDP-43 inclusions","volume":"8","author":"Watanabe","year":"2020","journal-title":"Acta Neuropathol Commun"},{"issue":"24","key":"10.1007\/s13311-022-01247-2_bib90","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1212\/WNL.0b013e318278b618","article-title":"Ataxin-1 and ataxin-2 intermediate-length PolyQ expansions in amyotrophic lateral sclerosis","volume":"79","author":"Conforti","year":"2012","journal-title":"Neurology"},{"issue":"3","key":"10.1007\/s13311-022-01247-2_bib91","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1212\/WNL.0000000000001159","article-title":"ATXN2 polyQ intermediate repeats are a modifier of ALS survival","volume":"84","author":"Chio","year":"2015","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01247-2_bib92","doi-asserted-by":"crossref","first-page":"178.e1","DOI":"10.1016\/j.neurobiolaging.2016.11.010","article-title":"ATXN2 trinucleotide repeat length correlates with risk of ALS","volume":"51","author":"Sproviero","year":"2017","journal-title":"Neurobiol Aging"},{"issue":"27","key":"10.1007\/s13311-022-01247-2_bib93","doi-asserted-by":"crossref","first-page":"9133","DOI":"10.1523\/JNEUROSCI.0996-12.2012","article-title":"ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation and increase TDP-43 pathological modifications","volume":"32","author":"Hart","year":"2012","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-022-01247-2_bib94","doi-asserted-by":"crossref","first-page":"598517","DOI":"10.3389\/fncel.2020.598517","article-title":"Stress granule dysregulation in amyotrophic lateral sclerosis","volume":"14","author":"Dudman","year":"2020","journal-title":"Front Cell Neurosci"},{"issue":"3","key":"10.1007\/s13311-022-01247-2_bib95","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1083\/jcb.201302044","article-title":"Stress granules as crucibles of ALS pathogenesis","volume":"201","author":"Li","year":"2013","journal-title":"J Cell Biology"},{"issue":"49","key":"10.1007\/s13311-022-01247-2_bib96","doi-asserted-by":"crossref","first-page":"41310","DOI":"10.1074\/jbc.M112.398099","article-title":"Roles of ataxin-2 in pathological cascades mediated by TAR DNA-binding protein 43 (TDP-43) and fused in sarcoma (FUS)*","volume":"287","author":"Nihei","year":"2012","journal-title":"J Biol Chem"},{"issue":"7650","key":"10.1007\/s13311-022-01247-2_bib97","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nature22038","article-title":"Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice","volume":"544","author":"Becker","year":"2017","journal-title":"Nature"},{"key":"10.1007\/s13311-022-01247-2_bib98","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.3389\/fnins.2019.01310","article-title":"ALS Genetics, mechanisms, and therapeutics: where are we now?","volume":"13","author":"Mejzini","year":"2019","journal-title":"Front Neurosci-switz"},{"issue":"7650","key":"10.1007\/s13311-022-01247-2_bib99","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nature22044","article-title":"Antisense oligonucleotide therapy for spinocerebellar ataxia type 2","volume":"544","author":"Scoles","year":"2017","journal-title":"Nature"},{"issue":"6","key":"10.1007\/s13311-022-01247-2_bib100","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00401-019-01962-9","article-title":"Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD","volume":"137","author":"Pottier","year":"2019","journal-title":"Acta Neuropathol"},{"issue":"2","key":"10.1007\/s13311-022-01247-2_bib101","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41593-018-0293-z","article-title":"Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration","volume":"22","author":"Melamed","year":"2019","journal-title":"Nat Neurosci"},{"issue":"11","key":"10.1007\/s13311-022-01247-2_bib102","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1172\/JCI139741","article-title":"Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia","volume":"130","author":"Prudencio","year":"2020","journal-title":"J Clin Invest"},{"issue":"7899","key":"10.1007\/s13311-022-01247-2_bib103","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41586-022-04436-3","article-title":"TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A","volume":"603","author":"Brown","year":"2022","journal-title":"Nature"},{"issue":"7899","key":"10.1007\/s13311-022-01247-2_bib104","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41586-022-04424-7","article-title":"TDP-43 represses cryptic exon inclusion in the FTD\u2013ALS gene UNC13A","volume":"603","author":"Ma","year":"2022","journal-title":"Nature"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01247-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-022-01247-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923010735?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923010735?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01247-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:52:16Z","timestamp":1761807136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923010735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":104,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1878747923010735"],"URL":"https:\/\/doi.org\/10.1007\/s13311-022-01247-2","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antisense Oligonucleotides for the Study and Treatment of ALS","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-022-01247-2","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}